• Decrease font size
  • Return font size to normal
  • Increase font size
U.S. Department of Health and Human Services

Advisory Committees

  • Print
  • Share
  • E-mail

Final Agenda for the March 22, 2010 Meeting of the Pediatric Advisory Committee

Monday, March 22, 2010
Bethesda Marriott Hotel,
5151 Pooks Hill Road,
Bethesda, Maryland, 20814

 

8:00 a.m. Welcome and Introductory Remarks

Geoffrey Rosenthal, MD, PhD,
Chair of Pediatric Advisory Committee
Director of Pediatric & Congenital Heart Center
Executive Director, Critical Care Services
University of Maryland Medical Center
Hospital for Children

Doreen Kezer, MSN
Executive Secretary, Pediatric Advisory Committee
Office of Science and Health Coordination
OC, FDA

8:05 a.m.

Agenda Overview

 

Dianne Murphy, MD, Director
Office of Pediatric Therapeutics
OC, FDA
8:15 a.m. Anthelios 40  sunscreen
Cardiolite (technetium Tc-99m)
Nasacort AQ (triamcinolone)
Viramune (nevirapine)
Judith Cope, MD, MPH, Medical Officer,
Office of Pediatric Therapeutics
OC, FDA
  Abbreviated Presentations  
  Opportunity for questions  
8:30 a.m. Introduction to CBER Vaccines Robert Wise, MD, MPH, Deputy Director
Division of Epidemiology
CBER, FDA
8:50 a.m. DAPTACEL (Diphtheria and Tetanus Toxoids and Acellular Pertussis Vaccine Adsorbed) Standard Review of Adverse Events    David Menschik, MD, MPH, Medical Officer
Division of Epidemiology
CBER, FDA
  Questions and Recommendation  
9:10 a.m. PENTACEL (Diphtheria and Tetanus Toxoids and Acellular Pertussis Adsorbed, Inactivated Poliovirus and Haemophilus b Conjugate (Tetanus Toxoid Conjugate) Vaccine)
Standard Review of Adverse Events
Jane Woo, MD, MPH, Medical Officer
Division of Epidemiology
CBER, FDA
  Questions and Recommendation  
9:30 a.m. KINRIX (Diphtheria and Tetanus Toxoids and Acellular Pertussis Adsorbed and Inactivated Poliovirus Vaccine)
Standard Review of Adverse Events
Jane Woo, MD, MPH, Medical Officer
Division of Epidemiology
CBER, FDA
  Questions and Recommendation  
10:15 a.m. Break  
10:30 a.m. Valtrex (valacyclovir)
Standard Review of Adverse Events
Felicia Collins, MD, MPH, Medical Officer
Pediatric & Maternal Health Staff,
Office of New Drugs, CDER, FDA
  Questions and Recommendation  
10:45 a.m. Zmax (azithromycin)
Standard Review of Adverse Events
Virginia Elgin, MD, Medical Officer
Pediatric & Maternal Health Staff,
Office of New Drugs, CDER, FDA
  Questions and Recommendation  
11:00 a.m. Follow-up on FDA Early Communication Regarding Reports of Liver-Related Adverse Events in Patients Taking Orlistat Lisa Mathis, MD, Director,
Pediatric Maternal Health Staff
Office of New Drugs, CDER, FDA
11:30 a.m. Lunch  
1:00 p.m. Open Public Hearing  
1:15 p.m. Topical Calcineurin Inhibitors: Elidel and Protopic Follow-up Presentation: Introduction and Background; Division Update on Registries Amy Woitach, DO, MS, Medical Officer, DDDP
CDER, FDA
1:45 p.m. Malignancies in Children:  Background Rates Logan Specter, Ph.D
Epidemiology
University of Minnesota
2:30 p.m. Safety and Drug Utilization Review Lois LaGrenade, MD, MPH, Medical Officer
Division of Pharmacoviligance I
OSE, CDER, FDA
3:00 p.m Sponsor Presentations Novartis Elidel (pimecrolimus)
Astellas Protopic (tacrolimus)
  Clarification Questions  
  Questions and Recommendation  
4:30 p.m. ROTARIX (Rotavirus Vaccine, Live, Oral)
Standard Review of Adverse Events
Wei Hua, MD, MPH, Medical Officer,
Division of Epidemiology
CBER, FDA
  Questions and Recommendation  
5:30 p.m.  Adjourn Geoffrey Rosenthal, MD, PhD, Chair
Director of Pediatric & Congenital Heart Center
Executive Director, Critical Care Services
University of Maryland Medical Center
Hospital for Children